HOME >> BIOLOGY >> NEWS
Research funded to test new breast cancer medicine

BLACKSBURG, Va., July 9, 2001 Virginia Tech researchers in human nutrition and dairy science are beginning animal trials to test a new compound against breast cancer, thanks to a grant from Virginias Commonwealth Health Research Board (CHRB).

Barbara Davis, an assistant professor in human nutrition, foods, and exercise, is the lead investigator in a research project that will test the novel Schiff base-forming drug, which is known to strengthen the immune system -- an important mechanism for fighting cancer. Research from Davis lab has shown that this drug can kill breast cancer cells growing outside the body, without the help of the immune system.

Davis has already reported that a molecule of similar structure, vitamin B6, is effective at killing breast cancer cells, but the drug she is now testing can safely be used in humans at higher doses than B6 and therefore may represent a better breast cancer treatment option.

In collaboration with Mike Akers, the Alphin Professor of Dairy Science at Virginia Tech, and Prakash Nagarkatti, a researcher at the Medical College of Virginia, Davis will treat breast cancer in two types of mice, those with normal and those with weakened immune systems.

These experiments will help determine the involvement of the immune system in the cancer-killing ability of this drug. More importantly, they will show whether it is effective in treating breast cancer in the body.

The project is especially significant to Virginians, because mortality from breast cancer in Virginia is higher than the national average, although the incidence of breast cancer is below the national average, said Davis.


'"/>

Contact: Jean Elliott
elliottj@vt.edu
540 -231-5915
Virginia Tech
9-Jul-2001


Page: 1

Related biology news :

1. Researchers determine genetic cause of Timothy syndrome
2. Researchers find color sensitive atomic switch in bacteria
3. Schepens Eye Research Institute receives Roadmap grant to develop center for curing eye diseases
4. Researchers identify protein promoting vascular tumor growth
5. Researchers devise potent new tools to curb ivory poaching
6. Researchers create nanotubes that change colors, form nanocarpet and kill bacteria
7. Researchers ID chlorophyll-regulating gene
8. Environmental issues center of Inland Northwest Research Alliance 4th Annual Symposium
9. Research suggests new avenue for stopping, preventing colon cancer
10. Researchers develop fast track way to discover how cells are regulated
11. Research on carbohydrate metabolism receives historical recognition

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Research funded test new breast cancer medicine

(Date:10/15/2014)... , Oct. 15, 2014 Sandata Technologies, ... home and community-based care, today announced it released ... Sandata,s Santrax® Electronic Visit Verification™ Solution (EVV™)  for ... a home health company founded in 1996 and ... . The study details the ...
(Date:10/15/2014)... linked increased resistance to bacterial pneumonia in female mice ... estrogen. , Females are naturally more resistant to respiratory ... has shown that increased resistance to bacterial pneumonia in ... synthase 3 (NOS3). They also show that this enzyme ... sex hormone estrogen. , The team, lead by Professor ...
(Date:10/14/2014)... Cancer Research shows SIRT6—a protein known to ... the development of skin cancers by turning on an ... skin cells. , Previously considered protective, SIRT6 is part ... help regulate genomic stability and prevent some of the ... damage, which can lead to cancer. This study, in ...
Breaking Biology News(10 mins):Sandata Announces Case Study with Quality Care Services, Inc. 2Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2
(Date:10/25/2014)... October 24, 2014 Today, Nerium International, ... the winners of its “Reflect Your Youth” contest, an ... only seen a difference in their skin since using ... new outlook on life as a result of their ... as an effort by Nerium International to inspire conversations ...
(Date:10/25/2014)... , October 24, 2014 ... clinical-stage pharmaceutical company focused on the development of oral ... Nadav Kidron will present at FireRock Capital,s ... Capital,s Annual Micro-Cap Conference ,Date: Tuesday, October 28, 2014 ... New York City , ...
(Date:10/25/2014)... 2014 Research and Markets has ... Product , Research Area & by End User - ... In this report, the global epigenetics ... areas, and end users. The product segments of the ... & consumables, kits, and reagents. The subsegments of the ...
(Date:10/22/2014)... DUBLIN and BOSTON , ... ACT ), a leading global specialty pharmaceutical company, and ... been granted an exclusive option to acquire Rhythm,s wholly ... (RM-131), a peptide ghrelin agonist, for the treatment of ... Rhythm has completed a successful Phase 2 trial ...
Breaking Biology Technology:Nerium International™ Inspires Conversation About the Journey of Aging with “Reflect Your Youth” Contest 2Oramed to Present at the FireRock Annual Micro-Cap Conference 2Oramed to Present at the FireRock Annual Micro-Cap Conference 3Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5
Cached News: